🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Lupin Limited LUPIN NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.lupin.com
Company Profile ↓
₹2,110.00
+9.34% 1Y
Mkt Cap₹96,464.79 Cr
P/E18.12
P/B4.81
Div. Yield0.75%
52W High₹2,514.80
52W Low₹1,876.10
Book Value₹491.02
EPS (TTM)₹116.44

Company Overview

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 23.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 28.3%.

Consistent Profit Growth

Net profit has compounded at 131.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.1% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 18.1, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 19.4%.

Recent Developments

  • Mar 2026 Revenue of ₹27,487.54 Cr (+23.9% YoY); net profit ₹5,332.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.9%, earnings +62.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.1%, profit CAGR 131.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.10%
1 Year:23.86%

Compounded Profit Growth

5 Years:131.46%
1 Year:62.51%

Stock Price Performance

1 Year:+9.34%
6 Months:-9.32%
3 Months:-6.13%
1 Month:-11.53%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 37% of range
₹1,876.10 ₹2,514.80
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)25.98 · Oversold
Price Performance
1M-11.53%
3M-6.13%
6M-9.32%
1Y+9.34%
Valuation vs Sector

P/E of 18.12 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 23.8%.
  • Healthy ROCE of 28.3%.
  • Compounding revenue at 19.1% over 5 years.
  • Profit CAGR of 131.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.12
Industry PE
41.64
Forward P/E
20.61
PEG Ratio
-
Book Value
₹491.02
Price to Book
4.81
P/S
3.87
EV/EBITDA
13.56
Dividend Yield
0.75%

Growth (CAGR)

Revenue 5Y
19.10%
Profit 5Y
131.46%
Revenue (YoY)
23.86%
Earnings (YoY)
62.51%

Profitability & Returns

ROCE
28.33%
ROE
23.76%
ROA
13.90%
Profit Margin
19.40%
Op Margin
24.81%
Gross Margin
70.49%
EPS (Latest Qtr)
₹30.89
EPS (TTM)
₹116.44

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.42
Current Ratio
1.90
Debt
₹6,616.18 Cr
Total Assets
₹38,364.83 Cr
Current Assets
₹24,027.38 Cr
Working Capital
₹11,376.14 Cr

Ownership

Promoter Holding
47.02%
Chg in Prom Hold
-0.00%
FII / Inst Holding
35.62%
Chg in FII Hold
0.10%

Financial Snapshot

Enterprise Value
₹96,464.79 Cr
Total Revenue (TTM)
₹27,487.54 Cr
EBITDA
₹8,660.55 Cr
Free Cash Flow
₹5,279.65 Cr
Operating Cash Flow
₹7,334.50 Cr
Shares Outstanding
₹45.72 Cr
Gross Margin
70.49%
Payout Ratio
10.31%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,110.00 18.12 ₹96,464.79 Cr 0.75% 28.33% 23.76% 19.10% 131.46%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 4,430.00 Cr4,814.00 Cr5,039.00 Cr5,197.00 Cr4,961.00 Cr5,600.00 Cr--5,562.20 Cr6,163.75 Cr7,048.00 Cr7,100.45 Cr7,391.91 Cr8,217.23 Cr
Cost of Revenue --------1,686.20 Cr1,771.93 Cr-1,878.13 Cr1,851.63 Cr2,089.24 Cr
Gross Profit --------3,876.00 Cr4,391.82 Cr-5,222.32 Cr5,540.28 Cr6,127.99 Cr
Operating Expenses 3,852.00 Cr3,958.00 Cr4,121.00 Cr4,159.00 Cr3,964.00 Cr4,359.00 Cr--2,977.06 Cr3,049.43 Cr4,706.00 Cr3,325.79 Cr3,816.00 Cr4,029.48 Cr
Operating Income 314.00 Cr621.00 Cr670.00 Cr781.00 Cr540.00 Cr993.00 Cr--898.94 Cr1,342.39 Cr2,024.00 Cr1,896.53 Cr1,724.28 Cr2,098.51 Cr
EBITDA 578.00 Cr856.00 Cr918.00 Cr1,038.00 Cr997.00 Cr1,241.00 Cr--1,378.12 Cr1,806.28 Cr2,341.00 Cr1,949.98 Cr2,494.95 Cr2,491.94 Cr
Interest Expense 93.00 Cr86.00 Cr81.00 Cr74.00 Cr71.00 Cr68.00 Cr--89.10 Cr91.76 Cr108.00 Cr114.98 Cr120.16 Cr109.64 Cr
Pretax Income 258.00 Cr559.00 Cr630.00 Cr736.00 Cr498.00 Cr993.00 Cr--895.84 Cr1,415.54 Cr2,007.00 Cr1,522.04 Cr1,928.00 Cr2,017.36 Cr
Tax Provision 15.48 Cr106.21 Cr132.30 Cr117.76 Cr129.48 Cr188.67 Cr--113.46 Cr194.08 Cr521.82 Cr341.53 Cr459.33 Cr600.38 Cr
Net Income 242.00 Cr453.00 Cr495.00 Cr619.00 Cr368.00 Cr806.00 Cr--772.52 Cr1,219.03 Cr1,485.00 Cr1,175.55 Cr1,460.34 Cr1,415.00 Cr
Diluted EPS 5.199.9410.7613.477.8917.58--16.8726.6232.3625.6731.8930.89

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 12,770.00 Cr14,256.00 Cr17,367.00 Cr15,797.00 Cr14,665.00 Cr15,375.00 Cr15,163.00 Cr-16,269.98 Cr19,656.34 Cr22,192.11 Cr27,487.54 Cr
Cost of Revenue --------7,264.89 Cr7,146.78 Cr7,455.96 Cr8,110.75 Cr
Gross Profit --------9,005.09 Cr12,509.56 Cr14,736.15 Cr19,376.79 Cr
Operating Expenses 9,146.00 Cr10,564.00 Cr12,865.00 Cr12,649.00 Cr12,104.00 Cr13,020.00 Cr12,596.00 Cr-8,115.65 Cr9,712.92 Cr10,390.93 Cr12,558.35 Cr
Operating Income 3,189.00 Cr3,204.00 Cr3,590.00 Cr2,062.00 Cr1,715.00 Cr1,385.00 Cr1,680.00 Cr-889.44 Cr2,796.64 Cr4,345.22 Cr6,818.44 Cr
EBITDA 3,624.00 Cr3,691.00 Cr4,502.00 Cr3,148.00 Cr2,561.00 Cr2,355.00 Cr2,567.00 Cr-1,837.39 Cr3,898.12 Cr5,454.79 Cr8,660.55 Cr
Interest Expense 10.00 Cr59.00 Cr153.00 Cr204.00 Cr302.00 Cr363.00 Cr141.00 Cr-240.21 Cr279.04 Cr270.53 Cr412.50 Cr
Pretax Income 3,415.00 Cr3,329.00 Cr3,543.00 Cr547.00 Cr1,503.00 Cr887.00 Cr1,676.00 Cr-716.49 Cr2,422.27 Cr4,015.00 Cr6,872.55 Cr
Tax Provision 956.20 Cr1,065.28 Cr992.04 Cr289.91 Cr886.77 Cr1,153.10 Cr452.52 Cr-268.80 Cr486.70 Cr708.74 Cr1,517.08 Cr
Net Income 2,444.00 Cr2,270.00 Cr2,565.00 Cr258.00 Cr615.00 Cr-270.00 Cr1,228.00 Cr-430.08 Cr1,914.48 Cr3,281.62 Cr5,332.84 Cr
Diluted EPS 53.4750.1756.635.5613.40-5.9526.81-9.4141.8771.69116.44

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 13,054.00 Cr22,298.00 Cr26,212.00 Cr26,020.00 Cr27,661.00 Cr24,810.00 Cr23,430.00 Cr-22,955.93 Cr23,997.18 Cr29,204.88 Cr38,364.83 Cr
Current Assets --------12,451.30 Cr13,447.65 Cr16,798.58 Cr24,027.38 Cr
Cash & Equivalents --------1,231.81 Cr983.28 Cr1,543.69 Cr4,167.73 Cr
Inventory --------4,491.76 Cr4,953.90 Cr5,476.35 Cr6,083.25 Cr
Receivables --------4,480.70 Cr4,692.05 Cr5,497.10 Cr6,604.06 Cr
Total Liabilities --------10,413.11 Cr9,623.73 Cr11,910.53 Cr15,851.46 Cr
Current Liabilities --------9,265.37 Cr8,501.50 Cr8,961.39 Cr12,651.24 Cr
Long Term Debt --------27.51 Cr01,766.23 Cr1,643.39 Cr
Total Debt 537.00 Cr7,178.00 Cr7,966.00 Cr7,143.00 Cr8,496.00 Cr6,305.00 Cr5,129.00 Cr-4,541.52 Cr2,921.77 Cr5,447.77 Cr6,616.18 Cr
Total Equity 8,874.00 Cr11,163.00 Cr13,497.00 Cr13,577.00 Cr13,742.00 Cr12,537.00 Cr13,803.00 Cr-12,464.50 Cr14,290.29 Cr17,203.50 Cr22,448.27 Cr
Shares Outstanding --------45.50 Cr45.57 Cr45.66 Cr45.72 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 2,733.00 Cr-382.00 Cr4,114.00 Cr1,751.00 Cr1,666.00 Cr1,469.00 Cr1,822.00 Cr-1,897.24 Cr3,648.36 Cr2,999.94 Cr7,334.50 Cr
Investing Cash Flow -1,034.00 Cr-6,769.00 Cr-2,527.00 Cr470.00 Cr-3,282.00 Cr1,107.00 Cr-1,240.00 Cr--1,286.77 Cr-1,712.20 Cr-4,171.89 Cr-3,864.59 Cr
Financing Cash Flow -197.00 Cr5,836.00 Cr433.00 Cr-1,492.00 Cr744.00 Cr-891.00 Cr-1,885.00 Cr--337.25 Cr-2,184.21 Cr1,731.88 Cr-845.87 Cr
Capital Expenditure -868.00 Cr-5,782.00 Cr-2,601.00 Cr-1,490.00 Cr-960.00 Cr-671.00 Cr-672.00 Cr--1,499.62 Cr-928.90 Cr-1,682.43 Cr-2,054.85 Cr
Free Cash Flow 1,865.00 Cr-6,164.00 Cr1,513.00 Cr261.00 Cr706.00 Cr798.00 Cr1,150.00 Cr-397.62 Cr2,719.46 Cr1,317.51 Cr5,279.65 Cr
Net Change in Cash 1,502.00 Cr-1,315.00 Cr2,019.00 Cr729.00 Cr-872.00 Cr1,685.00 Cr-1,303.00 Cr-273.22 Cr-248.05 Cr559.93 Cr2,624.04 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------55.3%63.6%66.4%70.5%
Operating Margin % 25.0%22.5%20.7%13.1%11.7%9.0%11.1%-5.5%14.2%19.6%24.8%
Net Margin % 19.1%15.9%14.8%1.6%4.2%-1.8%8.1%-2.6%9.7%14.8%19.4%
ROE % 27.5%20.3%19.0%1.9%4.5%-2.2%8.9%-3.5%13.4%19.1%23.8%
ROCE % --------6.5%18.0%21.5%26.5%

Shareholding Pattern

Insiders
47.02%
Institutions
35.62%
Public Float
67.24%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LUPIN

Google News Mon, 07 Sep 2026

Lupin receives USFDA approval for Modafinil tablets; share price down marginally - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWTctbjExMDlLWkxYQTFhYkcwT2pUVTNrYzRYMjVGQUQ1SE0zVDJiUVhTa3dRUjhXbk9YVmhWUl8tbTY4eXZ3SWx1Nkd4YlZrUjF1MTIzR0RCNkc1ZERxTXZpdWNoYzRWWC0tZVVnU0tBTVF3RHZSOUt6NWxUT3ZJYzBUaHN4LXF6QnRnNH…

Google News Mon, 10 Aug 2026

Lupin dips 4%, hits seven-week low; what's making the Street nervous? - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNMW5SRWh0SUY0a2lBZGdXcnU4c3dodzdGa1JZU2R1dV9lZlc1RUwyY2J4eG9SUlBibmFlTGdKejJlX0hLeDhvQ2lYeVJ4SlhkZzBIN2RwUzZKRDNoZ1VlbHhwUWZONGJFdDhKYW1adXd0bzVRNFhJU1VxWUkyRzJyTmZwcU5HYWo4Mlp5Ul…

Google News hu, 27 Aug 2026

Lupin shares recover from six-month low after 1.8% fall; Citi downgrades stock to Sell - TradingView

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxOdXZsU19qQzB4NktjXzg2NmVOeEp5MlhGNGlDVy1yLWplVXFoWTdIU1YxZkdsNzg4bEV2aFFSTVlJUDg2UFVqRTFiNEduOUZKTDdudTJRLS1xNFczRUwyYVU3Mm95elo2QlBQV2s0ZzdrbUt0MmFfUk0xeXdoOEZJNmlVTFlKQWxVR05tcF…

Google News Sun, 06 Sep 2026

Lupin Receives USFDA Form 483 With Three Observations For Somerset Facility - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOQzU1U0pIUUluYjZpMnVOVE50SkRfejlFU0dxZ2theE5jVWVtMWZIdmwyWnRaTXk0NkdfNU5NQ2hGb2JDcVBGQU4tUGJaSDliNjhfaTI2eGZ3MU9xc0g2bHFFdF9USVRvUGFuWWJNbm1FdHZzTkRJdXhIZUt2ZFpiWlhzLVpZakNMVlZleH…

Google News hu, 27 Aug 2026

Lupin Stock Outlook: Citi Downgrade Vs Bernstein Buy; Is The Pharma Stock A Buy Now? - Business Today

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPa0ZmSllkVVZHWDZVNUtybVJZYjFxSTFYVWlTdUt0bU5UM0U4OGFTUkdqVmM5a1BpdVVqclVsUWNhSUdLSVpsTmlTYXBXRldZLWl2dU1YYkdzeEVwcWZYTlowcnFuUDZjdzAzRVdnY1R4SFlNUDktWXBnN090V3NBSi1sNmxwS01qUnpmLV…

Google News ue, 18 Aug 2026

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPWU1JdzBuRnRCS1BleGtidkRXUW5LMGJIaU1xZ0k5TFBtVVNiNkpQa2NIaHVNdmh2V2liTG1UamVwQmJoUVF1YjgxRHEwQlJENTREc1FZaHFjdDd0dHVCbVJCM1pkTTgyNDQ4NmZURVFfZW5udEJlME9YUGZCbXo5NTdJWF8xcUtWZ3FHcz…

LUPIN — Frequently Asked Questions

What is the current share price of Lupin Limited (LUPIN)?

As of 2026-09-08 04:53 IST, Lupin Limited (LUPIN) trades at ₹2,110.00 on NSE. Its 52-week range is ₹1,876.10 to ₹2,514.80.

What is the market capitalisation of LUPIN?

Lupin Limited (LUPIN) has a market capitalisation of ₹96,464.79 Cr on NSE.

What is the P/E ratio of LUPIN?

LUPIN trades at a trailing price-to-earnings (P/E) ratio of 18.12. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.81.

Does LUPIN pay a dividend?

Lupin Limited (LUPIN) currently offers a dividend yield of 0.75%.

What is the return on equity (ROE) of LUPIN?

LUPIN has a return on equity (ROE) of 23.76%. Its return on capital employed (ROCE) is 28.33%.

Is LUPIN a good stock to buy?

This page provides a data-driven analysis of Lupin Limited (LUPIN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space